Clinical pharmacogenetics of ticagrelor: is there prospect?

In contemporary guidelines on the management of patients with acute coronary syndrome (ACS) an important place is given dual antiplatelet therapy. The relatively high frequency of complications and recurrences in such patients indicates the imperfections of modern approaches for antiplatelet therapy. The results of contemporary research showed a significant effect of the personalization of dual antiplatelet therapy with clopidogrel on outcomes and course of the ACS, because the influence of genetic factors on its antiplatelet effect is significantly. Drug of the third generation thienopyridines ticagrelor is not a prodrug like clopidogrel, however, its efficiency and safety is affected by many factors. This article describes current research in sphere of personalization of dual antiplatelet therapy of ACS on the basis of pharmacogenetics and discusses the potential of research the clinical pharmacogenetics of ticagrelor as a component of the personalization of dual antiplatelet therapy in patients with ACS.

Pharmacogenomics, ACS, clopidogrel, ticagrelor, personalized medicine, antiplatelet therapy, P2Y12-receptor inhibitors, P-450, CYP2C19, CYP 3A4, CYP3A5, ABCB1, SLCO1B1

1. Сведения о смертности населения по причинам смерти по Российской Федерации за январь – декабрь 2015 года (оперативные данные без учета окончательных медицинских свидетельств о смерти), Росстат gks.ru/free_doc/2015/demo/t3_3.xls

2. Patrick T. O’Gara, Frederick G. Kushner, Deborah D. Ascheim, Donald E. Casey, Jr, Mina K. Chung, James A. de Lemos et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, 2012. http://www.heart.org/idc/groups/heart-public/%40wcm/%40mwa/documents/downloadable/ucm_452392.pdf

3. Naghavi M., Libby P., Falk E., Casscells S.W., Litovsky S., Rumberger J. et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation. 2003 Oct 14; 108 (15): 1772–8.

4. Ritin Bomb M.D., Carrie S. Oliphant, Pharm D., Rami N., Khouzam M.D. Dual Antiplatelet Therapy after Coronary Artery Bypass Grafting in the Setting of Acute Coronary Syndrome, The American Journal of Cardiology. 2015.

5. Secco G.G., Parisi R., Mirabella F., Fattori R., Genoni G., Agostoni P., De Luca G., Marino P.N., Lupi A., Rognoni A. P2Y12 inhibitors: pharmacologic mechanism and clinical relevance. 2013.

6. Mathieu Pankert, Jacques Quilici, Thomas Cuisset. Role of Antiplatelet Therapy in Secondary Prevention of Acute Coronary Syndrome, Journal of Cardiovascular Translational Research. February 2012.

7. Dietmar Trenk, Willibald Hochholzer, Martin F. Fromm, Ligia-Emilia Chialda, Andreas Pahl, Christian M. Valina et al. Cytochrome P450 2C19 681G>A Polymorphism and High On-Clopidogrel Platelet Reactivity Associated With Adverse 1-Year Clinical Outcome of Elective Percutaneous Coronary Intervention With Drug-Eluting or Bare-Metal Stents, Journal of the American College of Cardiology. 2008; 51: 20.

8. Nader Makki, Theresa M. Brennan, Saket Girotra. Acute Coronary Syndrome, Journal of Intensive Care Medicine, published online 18 September 2013. http://jic.sagepub.com/content/early/2013/09/18/0885066613503294

9. Карпов Ю.А. Исследование PEGASUS-TIMI 54: улучшение долгосрочного прогноза после инфаркта миокарда. Журнал Атмосфера. Новости кардиологии. 2015; 2.

10. Musallam A., Orvin K., Perl L., Mosseri M., Arbel Y., Roguin A., Lev E.I. Effect of Modifying Antiplatelet Treatment to Ticagrelor in High-Risk Coronary Patients With Low Response to Clopidogrel (MATTIS), The Canadian Journal of Cardiology. 2016 Oct.

11. James J. DiNicolantonio, Fabrizio D’Ascenzo, Ales Tomek, Saurav Chatterjee, Asfandyar K. Niazi, Giuseppe Biondi-Zoccai. Clopidogrel is safer than ticagrelor in regard to bleeds: a closer look at the PLATO trial, International Journal of Cardiology. 2013.

12. Christian Hengstenberg, Adnan Kastrati. Genetic testing to guide therapy? Not for ticagrelor! European Heart Journal. June 17, 2015.

13. Christoph Varenhorst, Niclas Eriksson, Asa Johansson, Bryan J. Barratt, Emil Hagstrom, Axel Akerblom et al. Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. European Heart Journal, published. May 2, 2015.

14. Renli Teng,Ticagrelor. Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update, Clinical Pharmacokinetics Journal. 2015.